ECSP17069696A - Compuestos novedosos - Google Patents
Compuestos novedososInfo
- Publication number
- ECSP17069696A ECSP17069696A ECIEPI201769696A ECPI201769696A ECSP17069696A EC SP17069696 A ECSP17069696 A EC SP17069696A EC IEPI201769696 A ECIEPI201769696 A EC IEPI201769696A EC PI201769696 A ECPI201769696 A EC PI201769696A EC SP17069696 A ECSP17069696 A EC SP17069696A
- Authority
- EC
- Ecuador
- Prior art keywords
- novel compounds
- therapy
- processes
- formula
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504565.1A GB201504565D0 (en) | 2015-03-18 | 2015-03-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17069696A true ECSP17069696A (es) | 2018-02-28 |
Family
ID=53051992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201769696A ECSP17069696A (es) | 2015-03-18 | 2017-10-18 | Compuestos novedosos |
Country Status (31)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3419978T2 (ro) | 2016-02-24 | 2020-07-31 | Pfizer | Derivaţi de pirazolo[1,5-a]pirazin-4-il |
| WO2019034973A1 (en) | 2017-08-14 | 2019-02-21 | Pfizer Inc. | PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES |
| SG11202102441VA (en) * | 2018-09-13 | 2021-04-29 | Kissei Pharmaceutical Co Ltd | Imidazopyridinone compound |
| CN110950806A (zh) * | 2019-11-14 | 2020-04-03 | 安庆博曼生物技术有限公司 | 四乙基氯化铵催化嘧啶环羟基氯代制备方法 |
| JP7504822B2 (ja) * | 2020-03-12 | 2024-06-24 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物を含む医薬組成物 |
| US11718622B2 (en) | 2020-03-16 | 2023-08-08 | Exelixis Inc. | Heterocyclic adenosine receptor antagonists |
| CN117304171A (zh) * | 2020-04-20 | 2023-12-29 | 深圳市塔吉瑞生物医药有限公司 | 吡嗪取代的烟酰胺的固体形式及其制备和用途 |
| WO2022083569A1 (en) * | 2020-10-20 | 2022-04-28 | Amgen Inc. | Heterocyclic spiro compounds and methods of use |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| US20250034132A1 (en) | 2021-10-28 | 2025-01-30 | Insilico Medicine Ip Limited | Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof |
| CN118715015A (zh) * | 2021-12-17 | 2024-09-27 | 阿克比治疗有限公司 | 选择性phd1抑制剂化合物、组合物和使用方法 |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4209621A (en) | 1979-04-27 | 1980-06-24 | American Cyanamid Company | (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines |
| DK135184A (da) | 1983-03-03 | 1984-10-10 | Riker Laboratories Inc | Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner |
| US4572910A (en) * | 1983-03-03 | 1986-02-25 | Riker Laboratories, Inc. | Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings |
| EA006483B1 (ru) | 2000-06-30 | 2005-12-29 | Уайт | Замещенные триазолопиримидины в качестве противораковых средств |
| JP2010065026A (ja) | 2008-08-13 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤 |
| JP2010065024A (ja) | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤 |
| US8283465B2 (en) * | 2009-07-17 | 2012-10-09 | Japan Tobacco Inc. | Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent |
| JP2011168582A (ja) | 2010-01-21 | 2011-09-01 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤 |
| WO2014030716A1 (ja) * | 2012-08-23 | 2014-02-27 | 田辺三菱製薬株式会社 | ピラゾロピリミジン化合物 |
-
2015
- 2015-03-18 GB GBGB1504565.1A patent/GB201504565D0/en not_active Ceased
-
2016
- 2016-03-17 PH PH1/2017/501699A patent/PH12017501699B1/en unknown
- 2016-03-17 DK DK16715122.4T patent/DK3271357T3/da active
- 2016-03-17 MY MYPI2017703420A patent/MY194873A/en unknown
- 2016-03-17 EA EA201792057A patent/EA035739B1/ru unknown
- 2016-03-17 US US15/558,824 patent/US10287286B2/en active Active
- 2016-03-17 CR CR20170468A patent/CR20170468A/es unknown
- 2016-03-17 JP JP2017549107A patent/JP6726681B2/ja active Active
- 2016-03-17 KR KR1020177030091A patent/KR102609431B1/ko active Active
- 2016-03-17 GE GEAP201614608A patent/GEP20207095B/en unknown
- 2016-03-17 MX MX2017011902A patent/MX2017011902A/es active IP Right Grant
- 2016-03-17 NZ NZ735631A patent/NZ735631A/en unknown
- 2016-03-17 CA CA2979024A patent/CA2979024C/en active Active
- 2016-03-17 SG SG11201707280VA patent/SG11201707280VA/en unknown
- 2016-03-17 TN TNP/2017/000384A patent/TN2017000384A1/en unknown
- 2016-03-17 AU AU2016234209A patent/AU2016234209B2/en active Active
- 2016-03-17 PE PE2018000126A patent/PE20180656A1/es unknown
- 2016-03-17 PT PT167151224T patent/PT3271357T/pt unknown
- 2016-03-17 HU HUE16715122A patent/HUE047918T2/hu unknown
- 2016-03-17 UA UAA201708877A patent/UA123668C2/uk unknown
- 2016-03-17 BR BR112017019653-0A patent/BR112017019653B1/pt active IP Right Grant
- 2016-03-17 EP EP16715122.4A patent/EP3271357B1/en active Active
- 2016-03-17 WO PCT/JP2016/059782 patent/WO2016148306A1/en not_active Ceased
- 2016-03-17 ES ES16715122T patent/ES2774052T3/es active Active
- 2016-03-17 CN CN201680022416.0A patent/CN107531698B/zh active Active
-
2017
- 2017-09-03 IL IL254277A patent/IL254277B/en active IP Right Grant
- 2017-09-14 CO CONC2017/0009353A patent/CO2017009353A2/es unknown
- 2017-09-15 CL CL2017002354A patent/CL2017002354A1/es unknown
- 2017-09-18 DO DO2017000209A patent/DOP2017000209A/es unknown
- 2017-10-02 ZA ZA2017/06612A patent/ZA201706612B/en unknown
- 2017-10-18 EC ECIEPI201769696A patent/ECSP17069696A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17069696A (es) | Compuestos novedosos | |
| SV2017005514A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| ECSP17039611A (es) | Derivados de quinazolina utilizados para tratar el vih | |
| MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| CO2017013708A2 (es) | Macrociclos peptídicos contra acinetobacter baumannii. | |
| ECSP16074478A (es) | Compuestos novedosos | |
| ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| ECSP14013215A (es) | Compuestos novedosos | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX2018005725A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer. | |
| DOP2017000202A (es) | Desacetoxitubulisina h y análogos de esta | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
| ECSP16074482A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
| ECSP18056196A (es) | Derivados de indano | |
| ECSP17063489A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| UY36464A (es) | Compuestos de quinazolina |